Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | GAPDH | P04406 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18797900 | 0.98 | TYMP (0.39) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL18797879 | 0.98 | TYMP (0.39) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL18048079 | 0.95 | TYMP (0.40) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL18797906 | 0.95 | TYMP (0.37) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL18490592 | 0.95 | TYMP (0.37) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL18048072 | 0.94 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL18490271 | 0.93 | TYMP (0.39) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL22301451 | 0.92 | TYMP (0.38) | TYMPTAS1R3TAS1R1GAPDHP2RY12 | |
| SCHEMBL18048089 | 0.92 | TYMP (0.42) | TYMPGAPDHP2RY12PRMT6 | |
| SCHEMBL18992202 | 0.92 | TYMP (0.38) | TYMPTAS1R3TAS1R1GAPDHP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040053-B2 | Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200179431-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | Aduro Biotech, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| EP-3268035-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING | Aduro BioTech, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016145102-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179431-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | TYMP 1364/4885TAS1R3 496/4885TAS1R1 636/4885 |
| US-11040053-B2 | Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling | STING1, IRF3, CGAS | TYMP 2165/4885TAS1R3 346/4885TAS1R1 586/4885 |
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | STING1, IRF3, CGAS | TYMP 1876/4885TAS1R3 485/4885TAS1R1 581/4885 |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | TYMP 1369/4885TAS1R3 507/4885TAS1R1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.